Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-1910 in advanced solid tumors
NCT06205706Phase 2Active, not recruiting
- Sponsor
- BioInvent International
- Start
- Dec 2023
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of BI-1910 in solid tumor, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), sponsored by BioInvent International. Started Dec 2023; status: active, not recruiting.
02
Drugs
BI-1910
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06205706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205706.